Background: Copeptin is a reliable surrogate marker for the neurohypophyseal hormone vasopressin. Elevated plasma level of copeptin has been associated with cardiovascular and metabolic disease risk.
Objective: To investigate the association between copeptin and risk of dementia.
Methods: In all, 18,240 individuals from Malmö, Sweden, were examined between 2002 and 2006 (mean age 69.3 years, 69.8% men). Incident cases of dementia until 31 December 2009 were identified by linkage with the Swedish National Patient Register. To validate the dementia diagnoses, medical records as well as laboratory and neuroimaging data were carefully reviewed. Baseline level of copeptin was measured in frozen plasma in: (1) all participants who were diagnosed with dementia during follow-up, (2) a random sample of 5100 individuals of the cohort.
Results: During a median follow-up of 4.2 years, there were 374 incident dementia cases (age range 60–83 years at baseline): 120 were classified as Alzheimer’s disease (AD), 84 as vascular dementia (VaD), and 102 as mixed dementia. In logistic regressions adjusted for cardiovascular risk factors, baseline level of copeptin predicted incident VaD (Odds ratio (OR) 1.30 per 1 SD increase in log copeptin, 95% CI 1.03–1.64). Copeptin did not predict incidence of all-cause dementia (OR 1.05, 95% CI 0.94–1.18), AD (OR 0.97, 95% CI 0.79–1.18), or mixed dementia (OR 0.85, 95% CI 0.68–1.05).
Conclusion: Elevated plasma level of copeptin is a risk marker for incident VaD, but not for incident AD. This suggests that the vasopressin hormonal system might be involved in the development of VaD.
GorelickPB, ScuteriA, BlackSE, DecarliC, GreenbergSM, IadecolaC, LaunerLJ, LaurentS, LopezOL, NyenhuisD, PetersenRC, SchneiderJA, TzourioC, ArnettDK, BennettDA, ChuiHC, HigashidaRT, LindquistR, NilssonPM, RomanGC, SellkeFW, SeshadriS (2011) Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke42, 2672–2713.
2.
BarrettLK, SingerM, ClappLH (2007) Vasopressin: Mechanisms of action on the vasculature in health and in septic shockCrit Care Med35, 33–40.
3.
MorgenthalerNG, StruckJ, AlonsoC, BergmannA (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem52, 112–119.
4.
SaleemU, KhaleghiM, MorgenthalerNG, BergmannA, StruckJ, MosleyTHJr, KulloIJ (2009) Plasma carboxy-terminal provasopressin (copeptin): A novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab94, 2558–2564.
EnhorningS, WangTJ, NilssonPM, AlmgrenP, HedbladB, BerglundG, StruckJ, MorgenthalerNG, BergmannA, LindholmE, GroopL, LyssenkoV, Orho-MelanderM, Newton-ChehC, MelanderO (2010) Plasma copeptin and the risk of diabetes mellitus. Circulation121, 2102–2108.
7.
EnhorningS, BankirL, BoubyN, StruckJ, HedbladB, PerssonM, MorgenthalerNG, NilssonPM, MelanderO (2013) Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: The prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond)37, 598–603.
8.
EnhorningS, HedbladB, NilssonPM, EngstromG, MelanderO (2015) Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J169, 549–556.
9.
De MarchisGM, KatanM, WeckA, FluriF, FoerchC, FindlingO, SchuetzP, BuhlD, El-KoussyM, GensickeH, SeilerM, MorgenthalerN, MattleHP, MuellerB, Christ-CrainM, ArnoldM (2013) Copeptin adds prognostic information after ischemic stroke: Results from the CoRisk study. Neurology80, 1278–1286.
10.
MaiselA, XueY, ShahK, MuellerC, NowakR, PeacockWF, PonikowskiP, MockelM, HoganC, WuAH, RichardsM, CloptonP, FilippatosGS, Di SommaS, AnandIS, NgL, DanielsLB, NeathSX, ChristensonR, PotockiM, McCordJ, TerraccianoG, KremastinosD, HartmannO, von HaehlingS, BergmannA, MorgenthalerNG, AnkerSD (2011) Increased 90-daymortality in patients with acute heart failure with elevated copeptin: Secondary results from the Biomarkers in Acute Heart Failure (BACH) studyCirc Heart Fail4, 613–620.
11.
TentzerisI, JaraiR, FarhanS, PerkmannT, SchwarzMA, JaklG, WojtaJ, HuberK (2011) Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail13, 726–733.
12.
LipinskiMJ, EscarcegaRO, D’AscenzoF, MagalhaesMA, BakerNC, TorgusonR, ChenF, EpsteinSE, MiroO, LlorensP, GiannitsisE, LotzeU, LefebvreS, SebbaneM, CristolJP, Chenevier-GobeauxC, MeuneC, EggersKM, CharpentierS, TwerenboldR, MuellerC, Biondi-ZoccaiG, WaksmanR (2014) A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. Am J Cardiol113, 1581–1591.
13.
WiigEH, NielsenNP, MinthonL, WarkentinS (2002) , Pearson/Psych Corp, San Antonio, TX. A quick test of cognitive speed (AQT).
14.
TufvessonE, MelanderO, MinthonL, PerssonM, NilssonPM, StruckJ, NaggaK (2013) Diabetes mellitus and elevated copeptin levels in middle age predict low cognitive speed after long-term follow-up. Dement Geriatr Cogn Disord35, 67–76.
15.
BerglundG, NilssonP, ErikssonKF, NilssonJA, HedbladB, KristensonH, LindgardeF (2000) Long-term outcome of the Malmo preventive project: Mortality and cardiovascular morbidity. J Intern Med247, 19–29.
16.
LeosdottirM, WillenheimerR, PerssonM, NilssonPM (2011) The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: A cross-sectional analysis within the Malmo Preventive Project. Cardiovasc Diabetol10, 118.
17.
MokhtariA, Bellinetto-FordL, MelanderO, NilssonPM (2008) Determinants of increasing pulse pressure during 23 years’ follow-up as a marker of arterial stiffness and vascular ageing. Blood Press17, 291–297.
18.
PerssonM, HedbladB, NelsonJJ, BerglundG (2007) Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol27, 1411–1416.
19.
FriedewaldWT, LevyRI, FredricksonDS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem18, 499–502.
20.
LudvigssonJF, AnderssonE, EkbomA, FeychtingM, KimJL, ReuterwallC, HeurgrenM, OlaussonPO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health11, 450.
21.
Amercian Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental disorders, 3rd rev. ed., American Psychiatric Association, Washington, DC.
22.
Amercian Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental disorders, 4th ed., American Psychiatric Association, Washington, DC.
23.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
24.
TzourioC, LaurentS, DebetteS (2014) Is hypertension associated with an accelerated aging of the brain? . Hypertension63, 894–903.
25.
TombaughTN, McIntyreNJ (1992) The mini-mental state examination: A comprehensive review. J Am Geriatr Soc40, 922–935.
26.
Meyer-LindenbergA, DomesG, KirschP, HeinrichsM (2011) Oxytocin and vasopressin in the human brain: Social neuropeptides for translational medicineNat Rev Neurosci12, 524–538.
27.
BornJ, PietrowskyR, FehmHL (1998) Neuropsychological effects of vasopressin in healthy humans. Prog Brain Res119, 619–643.
28.
MiddletonLE, YaffeK (2010) Targets for the prevention of dementia. J Alzheimers Dis20, 915–924.
29.
WannametheeSG, WelshP, WhincupPH, LennonL, PapacostaO, SattarN (2014) N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: Population-based study. Eur J Heart Fail16, 25–32.
30.
KhanSQ, DhillonOS, O’BrienRJ, StruckJ, QuinnPA, MorgenthalerNG, SquireIB, DaviesJE, BergmannA, NgLL (2007) C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation115, 2103–2110.
31.
KerolaT, KettunenR, NieminenT (2011) The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly? . Int J Cardiol150, 123–129.
32.
DahlA, BergS, NilssonSE (2007) Identification of dementia in epidemiological research: A study on the usefulness of various data sources. Aging Clin Exp Res19, 381–389.
33.
JinYP, GatzM, JohanssonB, PedersenNL (2004) Sensitivity and specificity of dementia coding in two Swedish disease registries. Neurology63, 739–741.
